JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eisenfeld, A. J.
Right arrow Articles by Krakoff, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eisenfeld, A. J.
Right arrow Articles by Krakoff, L.
Journal of Pharmacology And Experimental Therapeutics, Vol. 156, Issue 1, 107-113, 1967
Copyright © 1967 by American Society for Pharmacology and Experimental Therapeutics

INHIBITION OF THE EXTRANEURONAL ACCUMULATION AND METABOLISM OF NOREPINEPHRINE BY ADRENERGIC BLOCKING AGENTS

Arnold J. Eisenfeld 1, Julius Axelrod 1, and Lawrence Krakoff 1

1 Laboratory of Clinical Science, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland

The accumulation of H3-norepinephrine and its metabolites has been measured in cocaine-treated, isolated, perfused rat hearts. This accumulation appears to occur outside of sympathetic neurons. Adrenergic blocking agents reduce this extraneuronal concentration of H3-norepinephrine and the metabolites. The alpha-adrenergic blocking agents are more potent than the beta-adrenergic blocking agents. The decreased concentrations of the metabolites in the presence of the adrenergic blocking agents do not appear to be related to inhibition of catechol-O-methyl transferase or monoamine oxidase but rather to the reduced concentrations of norepinephrine. It is proposed that the adrenergic blocking agents may inhibit an extraneuronal transport mechanism, thereby reducing the access of norepmnephrine to the intracellular metabolizing enzymes.

Submitted on August 8, 1966
Accepted on September 27, 1966




This article has been cited by other articles:


Home page
 JNMHome page
K.-H. Lee, B.-H. Ko, J.-Y. Paik, K.-H. Jung, J.-S. Bae, J.-Y. Choi, Y. S. Choe, and B.-T. Kim
Characteristics and Regulation of 123I-MIBG Transport in Cultured Pulmonary Endothelial Cells
J. Nucl. Med., March 1, 2006; 47(3): 437 - 442.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
J. Axelrod
Noradrenaline: Fate and Control of Its Biosynthesis
Science, August 13, 1971; 173(3997): 598 - 606.
[PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1967 by the American Society for Pharmacology and Experimental Therapeutics.